Kisspeptin-10
Master regulator of GnRH pulsatility — drives LH/FSH release and restores hormonal axis in hypogonadotrophic hypogonadism.
Research facts
| Half-life | ~30–60 minutes |
|---|---|
| Route | SubQ / IV |
| Typical dose | 1–10 nmol/kg (research doses vary widely) |
| Frequency | Pulsatile — every 90 minutes in research models, or twice daily SubQ |
| Solvent | Bacteriostatic water |
| pH | 5.5–7.5 |
| Stability | 30 days at +4°C |
Mechanism of action
Kisspeptin-10 is a 10-amino acid C-terminal fragment of kisspeptin (also called metastin), the endogenous ligand for the KISS1R receptor. The kisspeptin-GnRH axis is the master controller of the hypothalamic-pituitary-gonadal (HPG) axis — kisspeptin neurons integrate metabolic status, stress, and reproductive signals to regulate GnRH pulse frequency and amplitude. Kisspeptin-10 (the minimal bioactive fragment) activates KISS1R to trigger GnRH release, which drives LH and FSH secretion, and downstream testosterone/oestradiol production. In hypogonadotrophic hypogonadism (low LH/FSH with normal gonads), kisspeptin stimulation can restore the hormonal axis. Human Phase I/II trials demonstrate robust LH and testosterone responses.
Documented effects (research-model)
- Robust LH and FSH stimulation in human trials
- Testosterone restoration in hypogonadotrophic hypogonadism
- Ovulation induction research (women)
- HPG axis restoration post-steroid use
- Sexual desire enhancement via testosterone axis
- Hypothalamic amenorrhoea treatment research
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Research Protocol | 1–10 nmol/kg body weight SubQ | Twice daily or pulsatile (protocol-dependent) | 4–12 weeks | 5mg / 2mL BAC water |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- PT-141 MODERATE
Kisspeptin elevates testosterone (hormonal desire); PT-141 activates central arousal pathways. Comprehensive sexual health protocol. - Gonadorelin HIGH
Both stimulate the HPG axis at different levels — kisspeptin upstream of GnRH, gonadorelin as GnRH itself. Often combined in clinical HRT adjunct protocols.
Myths & misconceptions
Evidence gaps
- Optimal dosing protocol for sustained hormonal restoration not established.
- Long-term receptor desensitisation with sustained use not fully characterised.
- Efficacy in the context of exogenous testosterone use (HPG axis suppressed) not well studied.
Safety notes
Well-tolerated in Phase I/II trials. Transient injection site reactions. Monitor LH, FSH, testosterone, and oestradiol during research. Pulsatile administration may be more physiological than bolus dosing. Research context only.
Biomarkers to monitor
Primary-source citations
- PMID 17595387 — Administration of kisspeptin-54 stimulates gonadotropin release in healthy men (J Clin Endocrinol Metab. 2007)
- PMID 22628511 — Kisspeptin-10 rescues reproductive function in patients with hypothalamic amenorrhea (N Engl J Med. 2012)
Frequently asked
What is Kisspeptin-10?
Kisspeptin-10 (Kisspeptin-10 — Metastin Fragment (112–121)) is a research compound classified in our library as Tier C — Limited human trials; effect size uncertain.. Master regulator of GnRH pulsatility — drives LH/FSH release and restores hormonal axis in hypogonadotrophic hypogonadism.
What is the evidence tier for Kisspeptin-10?
We classify Kisspeptin-10 as Tier C: Limited human trials; effect size uncertain. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of Kisspeptin-10?
For Kisspeptin-10, typical research dose is 1–10 nmol/kg (research doses vary widely), route is SubQ / IV, half-life is ~30–60 minutes. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
What does Kisspeptin-10 stack well with?
Kisspeptin-10 stacks well with Gonadorelin. Both stimulate the HPG axis at different levels — kisspeptin upstream of GnRH, gonadorelin as GnRH itself. Often combined in clinical HRT adjunct protocols.
Is Kisspeptin-10 safe?
Well-tolerated in Phase I/II trials. Transient injection site reactions. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.